Reducing the toxicity of anticancer therapy: new strategies
Open accessThe DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
Cytoprotective agents offer opportunities to reduce the treatment-related toxicity of anticancer therapy and perhaps to increase the dose and dose intensity of radiation and chemotherapy. One such agent is amifostine, an organic thiophosphate. Amifostine selectively protects normal tissues and provides broad-spectrum protection for a variety of organs while remaining minimally toxic. Clinical studies have demonstrated that amifostine protects against myelotoxicity, nephrotoxicity, neurotoxicity, mucositis and esophagitis in patients treated with alkylating and platinum agents, paclitaxel and radiation therapy. In addition, preclinical studies suggest the possibility of protection against anthracycline-induced cardiotoxicity and radiation- and chemotherapy-induced mutagenicity. Preclinical and clinical studies have not demonstrated any diminution of antitumor efficacy. Amifostine is well tolerated in doses of 740 or 910 mg/m2. The most common side effects requiring treatment are transient hypotension, which responds to intravenous fluids, and nausea and vomiting, effectively treated with 5-HT3 antagonists and dexamethasone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Such treatments may cause diverse and even drastic side effects in patients [180,181,182,183,184,185,186].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., & Glick, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2101 · Cited by 463
Yuhas, J. M. (1980) · PubMed · Cited by 294
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Glover, D., Glick, J. H., Weiler, C., Fox, K., & Guerry, D. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.4.574 · Cited by 192
Jm, Y., & Čulo, F. (1980) · PubMed · Cited by 162
Calabro-Jones, P. M., Aguilera, J. A., Ward, J. F., Smoluk, G. D., & Fahey, R. C. (1988) · PubMed · Cited by 149
Cytoprotective agents for anthracyclines.
Dorr, R. T. (1996) · PubMed · Cited by 131
WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial.
Glover, D. J., Glick, J. H., Weiler, C., Hurowitz, S., & Kligerman, M. M. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.4.584 · Cited by 124
McDonald, S. A., Meyerowitz, C., Smudzin, T., & Rubin, P. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90562-2 · Cited by 123
Grdina, D. J., Nagy, B., Hill, C. K., Wells, R. L., & Peraino, C. (1985) · Carcinogenesis · doi:10.1093/carcin/6.6.929 · Cited by 117
Phase I/II trials of WR-2721 and cis-platinum
Glover, D. J., Glick, J. H., Weiler, C., Fox, K. R., Turrisi, A. T., & Kligerman, M. M. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90205-1 · Cited by 112
Research works printed but not linked: 2
- Yang JL, Fernandes DJ, Speicher L, Capizzi RL. Biochemical determinants of the cytoprotective effect of amifostine (meeting abstract). Proc Ann Meet Am Assoc Cancer Res 1995;36:1725.
- Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity [28
Cited by
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
Functionalized niosomes as a smart delivery device in cancer and fungal infection
Aparajay, P., & Dev, A. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.106052 · Cited by 154
Wattanapitayakul, S. K., Chularojmontri, L., Herunsalee, A., Charuchongkolwongse, S., Niumsakul, S., & Bauer, J. A. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960112.x · Cited by 131
Cancer drug development: The missing links
Kunnumakkara, A. B., Bordoloi, D., Sailo, B. L., Roy, N. K., Thakur, K. K., Banik, K., Shakibaei, M., Gupta, S. C., & Aggarwal, B. B. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219839163 · Cited by 112
Herman, E. H., Zhang, J., Chadwick, D. P., & Ferrans, V. J. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050048 · Cited by 122
“A similar protective activity has been observed in human clinical trials [15].”
Background
Metadata
- Authors
- Griggs, J. J.
- Affiliations
- University of Rochester Medicine (US)
- Corresponding author
- Griggs, Jennifer J
- ORCID
- Griggs, Jennifer J
- Venue
- Leukemia Research
- Publisher
- Elsevier BV
- Published
- 1998-05
- Volume
- 22
- Pages
- S27-S33
- ISSN
- 0145-2126 (ISSN-L)
- OpenAlex
- W2023645569
- Cited by
- 48
- References
- 35
- Citations by year
- 2026: 1 · 2025: 3 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2013: 2 · 2012: 2
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 301 d)
- Locations
- Leukemia Research (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Keywords
- amifostine, cytoprotective agents, chemotherapy toxicity, radiation toxicity, myelosuppression, nephrotoxicity, neurotoxicity, mucositis, esophagitis, alkylating agents, platinum agents, paclitaxel, anthracycline cardiotoxicity, mutagenicity, dose intensity, thiophosphates
- MeSH terms
- Antineoplastic Agents, Dose-Response Relationship, Drug, Amifostine, Humans, Neoplasms, Survival Rate, Treatment Outcome, Cytoprotection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reducing the toxicity of anticancer therapy: new strategies. https://app.cochat.ai/papers/10.1016/s0145-2126(98)00036-8
- The paper
- Griggs, J. J. (1998). Reducing the toxicity of anticancer therapy: new strategies. Leukemia Research. https://doi.org/10.1016/s0145-2126(98)00036-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.